Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
OPRX-106 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| OPRX-106 | DRUG | - |
OPRX-106 is an investigational small molecule being developed by Protalix BioTherapeutics, Inc. (PLX). It is currently in Phase 1 clinical development. The drug has been studied in a completed trial involving healthy volunteers to evaluate its safety and pharmacokinetics.
OPRX-106 is being studied for use in human volunteers, specifically to evaluate its safety and pharmacokinetics. It is an investigational drug in Phase 1 clinical development, and its intended therapeutic indication has not been established yet.
OPRX-106 is developed by Protalix BioTherapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol PLX. The company is conducting clinical research on this investigational drug.
OPRX-106 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. A Phase 1 trial has been completed to assess its safety and pharmacokinetics in healthy volunteers.
OPRX-106 has one completed clinical trial, identified as NCT02107833, titled 'Study to Evaluate the Safety and Pharmacokinetics of Oral OPRX-106 (TNFR-Fc Fusion Protein) in Healthy Volunteers.' This Phase 1 trial enrolled 18 participants and was an uncontrolled, non-randomized study.
OPRX-106 is also referred to as OPRX-106 in clinical trial records. The trial title describes it as an oral TNFR-Fc fusion protein, but the drug name used in development is OPRX-106.